A detailed history of Smith, Moore & Co. transactions in Eli Lilly & CO stock. As of the latest transaction made, Smith, Moore & Co. holds 8,287 shares of LLY stock, worth $6.36 Million. This represents 0.71% of its overall portfolio holdings.

Number of Shares
8,287
Previous 8,328 0.49%
Holding current value
$6.36 Million
Previous $7.54 Million 2.64%
% of portfolio
0.71%
Previous 0.78%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$772.14 - $960.02 $31,657 - $39,360
-41 Reduced 0.49%
8,287 $7.34 Million
Q2 2024

Aug 14, 2024

SELL
$724.87 - $909.04 $542,202 - $679,961
-748 Reduced 8.24%
8,328 $7.54 Million
Q1 2024

May 10, 2024

BUY
$592.2 - $792.28 $614,111 - $821,594
1,037 Added 12.9%
9,076 $7.06 Million
Q4 2023

Feb 13, 2024

BUY
$525.19 - $619.13 $165,434 - $195,025
315 Added 4.08%
8,039 $4.69 Million
Q3 2023

Nov 14, 2023

BUY
$434.7 - $599.3 $21,735 - $29,964
50 Added 0.65%
7,724 $4.15 Million
Q2 2023

Aug 11, 2023

BUY
$350.74 - $468.98 $474,551 - $634,529
1,353 Added 21.4%
7,674 $3.6 Million
Q1 2023

May 12, 2023

BUY
$310.63 - $364.82 $288,264 - $338,552
928 Added 17.21%
6,321 $2.17 Million
Q4 2022

Feb 13, 2023

BUY
$321.55 - $374.67 $18,649 - $21,730
58 Added 1.09%
5,393 $1.97 Million
Q3 2022

Nov 14, 2022

SELL
$296.48 - $337.87 $66,115 - $75,345
-223 Reduced 4.01%
5,335 $1.73 Million
Q2 2022

Aug 12, 2022

SELL
$278.73 - $327.27 $223,262 - $262,143
-801 Reduced 12.6%
5,558 $1.8 Million
Q1 2022

May 12, 2022

BUY
$234.69 - $291.66 $11,969 - $14,874
51 Added 0.81%
6,359 $1.82 Million
Q4 2021

Feb 08, 2022

BUY
$224.85 - $279.04 $76,673 - $95,152
341 Added 5.71%
6,308 $1.74 Million
Q3 2021

Nov 12, 2021

BUY
$221.6 - $272.71 $50,524 - $62,177
228 Added 3.97%
5,967 $1.38 Million
Q2 2021

Aug 10, 2021

SELL
$180.55 - $233.54 $3,611 - $4,670
-20 Reduced 0.35%
5,739 $1.32 Million
Q1 2021

May 14, 2021

BUY
$164.32 - $212.72 $31,220 - $40,416
190 Added 3.41%
5,759 $1.08 Million
Q4 2020

Feb 16, 2021

SELL
$130.46 - $172.63 $78,406 - $103,750
-601 Reduced 9.74%
5,569 $940,000
Q3 2020

Nov 12, 2020

BUY
$146.22 - $169.13 $78,812 - $91,161
539 Added 9.57%
6,170 $913,000
Q2 2020

Aug 10, 2020

BUY
$136.42 - $164.18 $119,640 - $143,985
877 Added 18.45%
5,631 $925,000
Q1 2020

May 15, 2020

BUY
$119.05 - $147.35 $19,048 - $23,576
160 Added 3.48%
4,754 $659,000
Q4 2019

Feb 07, 2020

BUY
$106.92 - $132.43 $129,052 - $159,843
1,207 Added 35.64%
4,594 $604,000
Q3 2019

Nov 07, 2019

SELL
$106.79 - $116.16 $2,349 - $2,555
-22 Reduced 0.65%
3,387 $379,000
Q2 2019

Aug 15, 2019

BUY
$110.79 - $129.32 $102,259 - $119,362
923 Added 37.13%
3,409 $378,000
Q1 2019

May 07, 2019

SELL
$111.31 - $131.02 $6,122 - $7,206
-55 Reduced 2.16%
2,486 $323,000
Q4 2018

Feb 15, 2019

SELL
$105.9 - $118.64 $211 - $237
-2 Reduced 0.08%
2,541 $294,000
Q3 2018

Nov 15, 2018

BUY
$85.86 - $107.31 $8,671 - $10,838
101 Added 4.14%
2,543 $273,000
Q2 2018

Aug 14, 2018

BUY
$75.7 - $86.88 $184,859 - $212,160
2,442 New
2,442 $208,000
Q1 2018

May 14, 2018

SELL
$74.21 - $87.6 $177,510 - $209,539
-2,392 Closed
0 $0
Q4 2017

Feb 09, 2018

BUY
$81.94 - $87.89 $81 - $87
1 Added 0.04%
2,392 $202,000
Q3 2017

Nov 02, 2017

BUY
$77.07 - $85.54 $184,274 - $204,526
2,391
2,391 $205,000

Others Institutions Holding LLY

About ELI LILLY & Co


  • Ticker LLY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 950,174,976
  • Market Cap $730B
  • Description
  • Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...
More about LLY
Track This Portfolio

Track Smith, Moore & Co. Portfolio

Follow Smith, Moore & Co. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Smith, Moore & Co., based on Form 13F filings with the SEC.

News

Stay updated on Smith, Moore & Co. with notifications on news.